Vanda Moves Ahead With Development Of Iloperidone, VEC-162
Following an end-of-Phase II meeting with FDA, Vanda plans to initiate a Phase III study of VEC-162 in sleep disorders in third quarter.
Following an end-of-Phase II meeting with FDA, Vanda plans to initiate a Phase III study of VEC-162 in sleep disorders in third quarter.